Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Other Accumulated Expenses (2018 - 2025)

TransMedics (TMDX) has 8 years of Other Accumulated Expenses data on record, last reported at $18.4 million in Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 90.42% year-over-year to $18.4 million; the TTM value through Dec 2025 reached $18.4 million, up 90.42%, while the annual FY2025 figure was $18.4 million, 90.42% up from the prior year.
  • Other Accumulated Expenses reached $18.4 million in Q4 2025 per TMDX's latest filing, up from $15.8 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $18.4 million in Q4 2025 and bottomed at $1.5 million in Q2 2021.
  • Average Other Accumulated Expenses over 5 years is $8.1 million, with a median of $5.5 million recorded in 2022.
  • Peak YoY movement for Other Accumulated Expenses: tumbled 41.35% in 2023, then soared 391.46% in 2024.
  • A 5-year view of Other Accumulated Expenses shows it stood at $4.6 million in 2021, then decreased by 5.58% to $4.4 million in 2022, then surged by 169.56% to $11.8 million in 2023, then decreased by 18.08% to $9.6 million in 2024, then soared by 90.42% to $18.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $18.4 million in Q4 2025, $15.8 million in Q3 2025, and $12.2 million in Q2 2025.